Volume 28, Issue 8 (Monthly_Nov 2017)                   Studies in Medical Sciences 2017, 28(8): 17-24 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghoreishi S, Sam M R. Treatment with 2-methyl- 3-pentyl-6-methoxyprodiginine isolated from serracia marcescens decreases cell viability and induces appoptosis in acute lymphoblaastic leukemia cells. Studies in Medical Sciences 2017; 28 (8) :17-24
URL: http://umj.umsu.ac.ir/article-1-3706-en.html
Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, Iran , s_mohammadreza@yahoo.com
Abstract:   (13190 Views)
Background & Aims: Acute lymphoblastic leukemia (ALL) is the most common malignancies in the world. Despite advances in treatment of patients with ALL, a subset of patients will have recurrent disease or refractory to chemotherapy and hematopoietic stem cell transplant. Consequently, assessment of the effectiveness of natural compounds with high efficacy and minimal side effects is warranted. In this regard, it has been shown that some of bacterial pigments such as prodigiosin isolated from cell wall of Serratia marcescens have dramatic anti-cancer activities. The aim of this study was to evaluate the effects of prodigiosin on the cell viability and cell number, cell proliferation and apoptosis in CCRF-CEM cell line that serves as a model for ALL cells.
Materials & Methods: Malignant cells were treated with 100, 200 and 400 nM prodigiosinfor 24, 48 and 72 h and cell proliferation-rates were measured by performing WST-1 assay. Furthermore, malignant cells were treated with the indicated concentrations of prodigiosin for 48 h and cell viabilities and cell numbers along with apoptotic-rates were determined by trypan blue staining method and flow cytometer respectively.
Results: Treatment of cells with increasing concentrations of prodigiosin significantly decreased
Proliferation -rates in a dose- and time-dependent manner compared to untreated cells. Specifically, after 72 h treatments with 100, 200 and 400 nM prodigiosin, proliferation-rates were measured to be%77.3 ± %1.5, %63 ± %2, and%46.3 ± %3.2 respectively as compared to untreated cells. Furthermore, following 48 h treatments with indicated concentrations of prodigiosin, the cell numbers and viabilities were decreased in a dose-dependent manner. Specifically, treatment with 400 nM prodigiosin resulted in 44% (4.5 × 105 cells) and 63% for cell number and viability respectively as compared to untreated cells. At the same conditions, apoptotic-rates (Early + Late) were measured to be 33.8% to 72.8% at the indicated prodigiosin concentrations ranging.
Conclusion: Prodigiosin decreased cell number and viability as well as cell proliferation-rates. This compound also increased apoptosis in CCRF-CEM cells. Therefore, this compound with high pro-apoptotic capacity represents an attractive anti-leukemic agent in ALL.
Full-Text [PDF 385 kb]   (1559 Downloads)    

1. Iran Cancer Registration Report, 2008. Tehran: Ministry of Health and Medical Education, Centre for Disease Control; 2011.
2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381 (9881): 1943-55.
3. Sumathi C, MohanaPriya D, Swarnalatha S, Dinesh, GM, Sekaran G. Production of prodigiosin using tannery fleshing and evaluating its pharmacological effects. Sci World J 2014; 2014:1–8. [PubMed]
4. Francisco R, Pe´rez-Toma´s R, Gime`nez-Bonafe´ P, Soto-Cerrato V, Gime´nez-Xavier P, Ambrosio S. Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur J Pharmacol 2007; 572:111–9. [PubMed]
5. Campàs C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17(4):746–50. [PubMed]
6. Soto-Cerrato V, Viñals F, Lambert JR, Pérez-Tomás R. The anticancer agent prodigiosin induces p21 WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol 2007; 74(9):1340–9. [Google Scholar]
7. Hassankhani R, Sam MR, Esmaeilou M, Ahangar P. Prodigiosin isolated from cell wall of Serratia marcescens alters expression of apoptosis-related genes and increases apoptosis in colorectal cancer cells. Med Oncol 2015; 32(1):366. [PubMed]
8. Sam S, Sam MR, Esmaeillou M, Safaralizadeh R. Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells. Pathol Oncol Res 2016; 22(4):715-23. [PubMed]
9. Chang C-C, Chen W-C, Ho T-F, Wu H-S, Wei Y-H. Development of natural anti-tumor drugs by microorganisms. J Biosci Bioeng 2011; 111(5):501–11. [PubMed]
10. Songia S, Mortellaro A, Taverna S, et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J Immunol 1997; 158(8):3987-95. [PubMed]
11. Denicourt C, Dowdy SF. Targeting apoptotic pathways in cancer cells. Science 2004; 305(5689):1411-3. [Google Scholar]
12. Yenkejeh RA, Sam MR, Esmaeillou M. Targeting survivin with prodigiosin isolated from cell wall of Serratia marcescens induces apoptosis in hepatocellular carcinoma cells. Hum Exp Toxicol 2017; 36(4):402-11. [PubMed]
13. Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralt E, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 2000; 131(3):585-93. [PubMed]
14. Dalili D, Fouladdel S, Rastkari N, Samadi N, Ahmadkhaniha R, Ardavan A, et al. Prodigiosin, the red pigment of Serratia marcescens, shows cytotoxic effects and apoptosis induction in HT-29 and T47D cancer cell lines. Nat Prod Res 2012; 26(22):2078-83. [PubMed]
15. Campas C, Dalmau M, Montaner B, Barragán M, Bellosillo B, Colomer D, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17(4):746-50. [PubMed]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb